Children's Hospital Los angeles
Los Angeles, California, 90027, United States
NCT Number: NCT05183282
Lagophthalmos is the inability to completely close the eyelids, which can be caused by conditions such as facial nerve dysfunction and eyelid scarring. Lagophthalmos causes evaporation of the tears, which in turn can lead to damage to the eye and permanent vision loss. Surgical interventions such as tarsorrhaphy or gold/platinum weight implantation can improve lagophthalmos, but these are invasive procedures that are not easily reversible. Temporary methods for treating lagophthalmos are also available, such as the use of medical tape or commercial eyelid closure devices. In the investigators' clinical experience, however, these methods are not well-tolerated by patients due to discomfort, especially due to the device sticking to the eyelashes. As a result, patients are at greater risk of non-compliance and subsequently experiencing ocular complications.
The Nictavi Tarsus Patch is a new medical device that uses a flexible material that conforms to the upper eyelid curvature while maintaining sufficient rigidity to keep the upper eyelid in a closed position. It also is designed to be placed above the eyelash line, which allows for enhanced comfort. There has been no study to date evaluating the Tarsus Patch for its effectiveness, safety, or tolerability.
The purpose of this study is to determine the effectiveness, safety, and tolerability of the Tarsus Patch in managing lagophthalmos in children and adolescents overnight. The investigators hypothesize that there will be a significant improvement in eyelid closure when using the Tarsus Patch when compared to not using any device and that over 90% of subjects will achieve complete eyelid closure with its use. The investigators also hypothesize there will be no complications related to the use of the Tarsus Patch, and that it will be considered by patients and parents to be comfortable, easy to use, and, overall, preferable to other available methods of nocturnal eyelid closure.
Looking for future studies?
Notify MeUp to 17 year
All sexes
Interventional
Not applicable
Los Angeles, California, 90027, United States
The investigators plan to recruit 20 children and adolescents (ages 0 to 17 years, inclusive) from the Children's Hospital Los Angeles (CHLA) ophthalmology clinics who have lagophthalmos affecting one or both eyes and have been recommended to use medical tape or other eyelid closure device to help keep their eyelids closed. The aims are to 1) objectively measure the improvement in lagophthalmos from baseline while using the Tarsus Patch, and 2) evaluate patients' and parents' experience with survey questions related to complications, comfort, ease of use, and preference for using the about the Tarsus Patch.
PROCEDURES INVOLVED
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
Other names: Nictavi Tarsus Patch
Time frame: This measurement is taken on day 1 during the study visit in clinic, which will take about 1 minute.
While the subject is being asked to close their eyes like they're going to sleep, the amount of lagophthalmos (the distance between the upper and lower eyelid) will be measured in millimeters. This measurement will be taken both while the subject is wearing the Tarsus Patch on the study eye and while the subject is not wearing the Tarsus Patch on the study eye. The difference in average lagophthalmos between when the Tarsus Patch is on versus off will be analyzed by paired t-test.
Time frame: This measurement is taken on day 1 during the study visit in clinic, which will take about 1 minute.
While the subject is being asked to look upwards, the interpalpebral fissure distance (distance between the upper and lower eyelid) will be measured in millimeters. This measurement will be taken both while the subject is wearing the Tarsus Patch on the study eye and while the subject is not wearing the Tarsus Patch on the study eye. The difference in average interpalpebral fissure distance between when the Tarsus Patch is on versus off will be analyzed by paired t-test.
Time frame: These surveys will be administered by phone on day 4, which is after the last day the subject wears the Tarsus Patch at home. The survey should take about 3 minutes per person.
The parent and subject (if 10 years of age or older) will be asked a series of likert-style questions that assess the comfort, ease of use, and preferability of the Tarsus Patch.
Time frame: The parental survey will be administered by phone on day 4, which is after the last day the subject wears the Tarsus Patch at home. The survey should take about 3 minutes per person.
Parents will be asked to report and elaborate during their survey if they felt that there were any complications or adverse effects related to using the patch.
Angeline Nguyen
Other
The Effectiveness, Safety, and Tolerability of the Nictavi Tarsus Patch in Managing Lagophthalmos in Children and Adolescents
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02988856
Blepharoptosis, Eye Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT04944498
Actinomycetales Infections, Bacterial Infections
Jakarta, DKI Jakarta, Indonesia
View Trial DetailsNCT01274689
Eye Diseases, Eye Manifestations
Berlin, State of Berlin, Germany
View Trial DetailsNCT06895902
Bell Palsy, Corneal Exposure
Edmonton, Alberta, Canada
View Trial Details